PDC and neoplasm: In fact, tumor-targeted therapy with BRAFi profoundly remodels the myeloid immune compartment in the TME with a transient accumulation of inflammatory monocytes and pDC including the recently described Mono (ACT) subtype resembling moDC by their marker expression.